Cardiovascular Risk 2006 - HIV - Clinical Care Options

Dyslipidemia and Other Cardiovascular Risk Factors in HIV

Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies

Date Posted: 1/16/2007
Lipid Effects of Antiretroviral Therapy

This tool enables you to review data from controlled studies on the lipid effects of recommended antiretroviral regimens for initial therapy as well as ‘switch strategies’ in patients on suppressive antiretroviral therapy.

Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies

Date Posted: 1/12/2007
HAART and the Heart: Managing Cardiovascular Risk Through Antiretroviral Individualization

Stefan Mauss, MD, PhD reviews options and outcomes of individual components of antiretroviral therapy on cardiovascular risk in HIV patients.

Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies

Faculty: Stefan Mauss MD, PhD

Released: 1/4/2007
HAART Initiation in an Overweight Female With Advanced HIV Disease

William G. Powderly, MD, discusses a case study exploring lipid abnormalities in patients with HIV infection and strategies for their management.

Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies

Faculty: William G. Powderly MD

Released: 1/2/2007
Management of Dyslipidemia in a 55-Year-Old Man at Very High Cardiovascular Risk

Judith S. Currier, MD, MSc, and Jesse Currier, MD, explore strategies to control dyslipidemia in a man with multiple cardiovascular risk factors.

Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies

Faculty: Judith S. Currier MD, MSc, Jesse Currier MD

Released: 12/26/2006
Application of Non–HIV-Specific Management Strategies for Dyslipidemia in HIV-Infected Patients

Pablo Tebas, MD, reviews the application of strategies used in the non–HIV-infected population for the management of dyslipidemia in HIV-infected patients.

Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies

Faculty: Pablo Tebas MD

Released: 12/14/2006
Cardiovascular Risk in HIV: Disease- and Treatment-Related Mechanisms in the HAART ERA

Peter Reiss, MD, PhD, discusses current understanding of the factors involved in increased cardiovascular disease risk and mortality associated with both HIV itself and treatment-related risk factors such as dyslipidemia.

Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies

Faculty: Peter Reiss MD, PhD

Released: 12/13/2006
Practical Approaches to Evaluating and Monitoring Cardiovascular Risk in HIV-Infected Patients

James H. Stein, MD, discusses practical methods and strategies for evaluating and monitoring risk for cardiovascular disease and mortality in HIV-infected patients.

Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies

Faculty: James H. Stein MD

Released: 12/1/2006
Management of a 45-Year-Old, HIV-Infected Man With Dyslipidemia While on HAART

Peter Reiss, MD, PhD, presents an interactive case exploring the optimal management of an HIV-infected patient on zidovudine/lamivudine plus lopinavir/ritonavir for 3 years who presents with concerns of increased risk of heart disease associated with long-term HAART.

Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies

Faculty: Peter Reiss MD, PhD

Released: 12/1/2006

Jointly sponsored by Medical Education Collaborative and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.

Other Sites

Topics

Educational Formats

Program Resources

User Resources

PDF
Video

Help
Site Tour
RSS

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Table of Contents

Latest Content

Dyslipidemia and Other Cardiovascular Risk Factors in HIV

Lipid Effects of Antiretroviral Therapy

HAART and the Heart: Managing Cardiovascular Risk Through Antiretroviral Individualization

HAART Initiation in an Overweight Female With Advanced HIV Disease

Management of Dyslipidemia in a 55-Year-Old Man at Very High Cardiovascular Risk

Application of Non–HIV-Specific Management Strategies for Dyslipidemia in HIV-Infected Patients

Cardiovascular Risk in HIV: Disease- and Treatment-Related Mechanisms in the HAART ERA

Practical Approaches to Evaluating and Monitoring Cardiovascular Risk in HIV-Infected Patients

Management of a 45-Year-Old, HIV-Infected Man With Dyslipidemia While on HAART

Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies
Table of Contents Modules • Cardiovascular risk in HIV during the HAART ERA • Evaluating and Monitoring Cardiovascular Risk in HIV • Dyslipidemia Management in HIV-Infected Patients • Application of Non–HIV-Specific Management for Dyslipidemia Interactive Case Challenges • HAART Initiation in Advanced HIV Disease • Managing Dyslipidemia While On HAART • Dyslipidemia in a Man at High Cardiovascular Risk Interactive Tool • Interactive Tool CCO Slidesets • Dyslipidemia and Other CV Risk Factors in HIV	Program Overview Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies Modules and interactive cases on managing cardiovascular risk. Latest Content 9 of 9 Shown Dyslipidemia and Other Cardiovascular Risk Factors in HIV Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies Date Posted: 1/16/2007 Lipid Effects of Antiretroviral Therapy This tool enables you to review data from controlled studies on the lipid effects of recommended antiretroviral regimens for initial therapy as well as ‘switch strategies’ in patients on suppressive antiretroviral therapy. Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies Date Posted: 1/12/2007 HAART and the Heart: Managing Cardiovascular Risk Through Antiretroviral Individualization Stefan Mauss, MD, PhD reviews options and outcomes of individual components of antiretroviral therapy on cardiovascular risk in HIV patients. Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies Faculty: Stefan Mauss MD, PhD Released: 1/4/2007 HAART Initiation in an Overweight Female With Advanced HIV Disease William G. Powderly, MD, discusses a case study exploring lipid abnormalities in patients with HIV infection and strategies for their management. Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies Faculty: William G. Powderly MD Released: 1/2/2007 Management of Dyslipidemia in a 55-Year-Old Man at Very High Cardiovascular Risk Judith S. Currier, MD, MSc, and Jesse Currier, MD, explore strategies to control dyslipidemia in a man with multiple cardiovascular risk factors. Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies Faculty: Judith S. Currier MD, MSc, Jesse Currier MD Released: 12/26/2006 Application of Non–HIV-Specific Management Strategies for Dyslipidemia in HIV-Infected Patients Pablo Tebas, MD, reviews the application of strategies used in the non–HIV-infected population for the management of dyslipidemia in HIV-infected patients. Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies Faculty: Pablo Tebas MD Released: 12/14/2006 Cardiovascular Risk in HIV: Disease- and Treatment-Related Mechanisms in the HAART ERA Peter Reiss, MD, PhD, discusses current understanding of the factors involved in increased cardiovascular disease risk and mortality associated with both HIV itself and treatment-related risk factors such as dyslipidemia. Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies Faculty: Peter Reiss MD, PhD Released: 12/13/2006 Practical Approaches to Evaluating and Monitoring Cardiovascular Risk in HIV-Infected Patients James H. Stein, MD, discusses practical methods and strategies for evaluating and monitoring risk for cardiovascular disease and mortality in HIV-infected patients. Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies Faculty: James H. Stein MD Released: 12/1/2006 Management of a 45-Year-Old, HIV-Infected Man With Dyslipidemia While on HAART Peter Reiss, MD, PhD, presents an interactive case exploring the optimal management of an HIV-infected patient on zidovudine/lamivudine plus lopinavir/ritonavir for 3 years who presents with concerns of increased risk of heart disease associated with long-term HAART. Source: Dyslipidemia and Other Cardiovascular Risk Factors in HIV: Causes, Clinical Significance, and Management Strategies Faculty: Peter Reiss MD, PhD Released: 12/1/2006 9 of 9 Shown Show 0 More Loading...	Jointly sponsored by Medical Education Collaborative and Clinical Care Options, LLC. Contact Info Educational grant provided by: Educational grants support only the CME-certified components of this program.